Johnson and Johnson await approval for distribution of vaccine

Johnson & Johnson takes the next big step in production for its coronavirus (COVID-19) vaccine requesting emergency authorization for use from the FDA. This request comes weeks after the release of the promising data of 66% effective in protecting against the virus.

Johnson & Johnson says that it could produce 1 billion doses of its COVID-19 vaccine — enough to vaccinate about an eighth of the world’s population — by the end of the year. https://t.co/oHnVcQeaqM

— Science News (@ScienceNews) February 5, 2021

If the new vaccine is approved, Johnson & Johnson will offer the third COVID-19 vaccine approved for emergency use in the U.S. and will also start the process of approval for worldwide use. The vaccine created by Johnson & Johnson was designed with accessibility that only requires a single-dose compared to competing vaccines.

Johnson & Johnson is ready to start distribution immediately after approval and promises to work with great urgency making the vaccine available to the public. The FDA scheduled a meeting with the Vaccines and Related Biological Products Advisory Committee to discuss the emergency use authorization on February 26.

The FDA will be following a similar protocol for other COVID-19 vaccines while making all the data available to the public. The committee will also cover the delivery methods of one dose that will be easier logically easier for health-care providers.

The pharmaceutical company #JohnsonandJohnson is ​preparing to seek ​U.S. government approval for its one-dose, easily transportable #COVID19 vaccine. And it's the 'one-dose' that's creating a lot of buzz. CGTN's John Terrett reports. pic.twitter.com/O8tGEp5sZk

— CGTN America (@cgtnamerica) February 4, 2021

The data will also cover the testing of COVID-19 variants with 66% protection against COVID-19 and 57% effectiveness against the South Africa (B.1.351) strain. Despite Johnson and Johnson having lower effective rates than the competing vaccines but offers 100% effectiveness in preventing hospitalization and death from COVID-19.

Despite having some competition, Johnson and Johnson have already created a deal back in August with the Department of Health and Human Services for $1 billion to provide 100 million doses. The contract for this deal also includes a stipulation giving the federal government the option of ordering ad additional 200 million doses.